Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284206 · ClinicalTrials.gov registry record · Phase 2
A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence
A Phase 2 study of Methamphetamine-dependence, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00284206 is a Phase 2 study of Methamphetamine-dependence that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 20 participants, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00284206, a Phase 2 study of Methamphetamine-dependence, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective of the Project. -Methamphetamine (MA) use is growing to epidemic proportions and existing treatments for MA dependence demonstrate sub-optimal efficacy. Research implicates heavy use of MA as at least a contributing agent to a variety of neuropsychiatric impairments including psychosis, mood disturbance, anxiety, cognitive deficits, and motor dysfunction. Initial study by this investigator suggests that agents like risperidone may also be beneficial to MA dependent individuals by decreasing MA use and improving cognitive function in early abstinence. Long-acting injectable risperidone may prove more efficacious given its receptor binding characteristics and potential to increase medication adherence. The study objective is to determine the safety and efficacy of treating MA dependence and the associated cognitive and psychiatric symptomatology with long-acting injectable risperidone.
Conditions Studied
Interventions
- DRUG long-acting injectable risperidone
Study Locations (1)
Washington
- VA Puget Sound Health Care System, Addictions Treatment Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00284206
The ClinicalTrials.gov registry entry for NCT00284206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (81% lower). The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methamphetamine-dependence appearing as the primary indexed condition, and to 1 intervention - of which long-acting injectable risperidone is the first listed.
NCT00284206 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00284206 about?
NCT00284206 is a clinical study titled "A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence". Objective of the Project. -Methamphetamine (MA) use is growing to epidemic proportions and existing treatments for MA dependence demonstrate sub-optimal efficacy. Research implicates heavy use of MA as at least a contributing agent to a variety of neuropsychiatric impairments including psychosis, m...
What is the current status of trial NCT00284206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-01. Estimated completion is 2007-08.
What conditions does trial NCT00284206 study?
This clinical trial studies the following conditions: Methamphetamine-dependence.
What interventions are being tested in trial NCT00284206?
The interventions under investigation include: long-acting injectable risperidone (DRUG).
Who is sponsoring clinical trial NCT00284206?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00284206 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
-
Study of Medical Treatment for Methamphetamine Addiction
COMPLETED · Phase 2
-
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
COMPLETED · Phase 2
-
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
COMPLETED · Phase 2
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.